Ian Spendlove

Summary

Affiliation: University of Nottingham
Country: UK

Publications

  1. ncbi request reprint Decay accelerating factor (CD55): a target for cancer vaccines?
    I Spendlove
    Cancer Research Campaign Academic Unit of Clinical Oncology, University of Nottingham, City Hospital, United Kingdom
    Cancer Res 59:2282-6. 1999
  2. ncbi request reprint The Role of CD97 in Regulating Adaptive T-Cell Responses
    Ian Spendlove
    Academic Clinical Oncology, The City Hospital, The University of Nottingham, Hucknall Road, Nottingham, NG5 1PB, UK
    Adv Exp Med Biol 706:138-48. 2011
  3. ncbi request reprint A therapeutic human anti-idiotypic antibody mimics CD55 in three distinct regions
    L Spendlove
    CRC Academic Unit of Clinical Oncology, University of Nottingham, City Hospital, GB
    Eur J Immunol 30:2944-53. 2000
  4. doi request reprint Differential subcellular localisation of the tumour suppressor protein LIMD1 in breast cancer correlates with patient survival
    Ian Spendlove
    Academic and Clinical Department of Oncology, University of Nottingham, Nottingham, United Kingdom
    Int J Cancer 123:2247-53. 2008
  5. ncbi request reprint Complement decay accelerating factor (DAF)/CD55 in cancer
    Ian Spendlove
    CR UK Academic Department of Clinical Oncology, Institute of Infections Immunity and Inflammation, The University of Nottingham, NG5 1PB, Nottingham, UK
    Cancer Immunol Immunother 55:987-95. 2006
  6. ncbi request reprint The role of CD97 in regulating adaptive T-cell responses
    Ian Spendlove
    The University of Nottingham, Academic Clinical Oncology, The City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK
    Adv Exp Med Biol 706:138-48. 2010
  7. pmc Upregulation of MICA on high-grade invasive operable breast carcinoma
    Zahra Madjd
    Academic Department of Clinical Oncology, Institute of Infections, Immunity and Inflammation, University of Nottingham, City Hospital, Nottingham, NG5 1PB, United Kingdom
    Cancer Immun 7:17. 2007
  8. ncbi request reprint A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55
    Gustav J Ullenhag
    Academic Department of Clinical Oncology, Nottingham City Hospital, Nottingham, United Kingdom
    Clin Cancer Res 12:7389-96. 2006
  9. ncbi request reprint Cytoplasmic expression of p27(kip1) is associated with a favourable prognosis in colorectal cancer patients
    Nicholas F S Watson
    Section of Gastrointestinal Surgery, University of Nottingham, E Floor, West Block, Queens Medical Centre, Derby Road, Nottingham, NG7 2UH, United Kingdom
    World J Gastroenterol 12:6299-304. 2006
  10. doi request reprint Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies?
    Timothy J Duncan
    Academic and Clinical Department of Oncology, University of Nottingham, Nottingham, UK
    Clin Cancer Res 14:3030-5. 2008

Collaborators

Detail Information

Publications44

  1. ncbi request reprint Decay accelerating factor (CD55): a target for cancer vaccines?
    I Spendlove
    Cancer Research Campaign Academic Unit of Clinical Oncology, University of Nottingham, City Hospital, United Kingdom
    Cancer Res 59:2282-6. 1999
    ..It is therefore a very intriguing target, because absence of the molecule makes the tumor cells susceptible to complement, whereas protective overexpression results in the antigen being a target for T-cell immunotherapy...
  2. ncbi request reprint The Role of CD97 in Regulating Adaptive T-Cell Responses
    Ian Spendlove
    Academic Clinical Oncology, The City Hospital, The University of Nottingham, Hucknall Road, Nottingham, NG5 1PB, UK
    Adv Exp Med Biol 706:138-48. 2011
    ..This raises a number of questions regarding the dual functions of CD55; regulating complement and stimulating T cells via CD97 interaction and any potential overlap in the consequences of these dual roles...
  3. ncbi request reprint A therapeutic human anti-idiotypic antibody mimics CD55 in three distinct regions
    L Spendlove
    CRC Academic Unit of Clinical Oncology, University of Nottingham, City Hospital, GB
    Eur J Immunol 30:2944-53. 2000
    ..These findings help identify the mechanism by which a human anti-idiotypic antibody is able to mimic a tumor-associated antigen and stimulate anti-tumor B and T cell responses...
  4. doi request reprint Differential subcellular localisation of the tumour suppressor protein LIMD1 in breast cancer correlates with patient survival
    Ian Spendlove
    Academic and Clinical Department of Oncology, University of Nottingham, Nottingham, United Kingdom
    Int J Cancer 123:2247-53. 2008
    ..The possible functions of LIMD1 localisation within the nucleus and cytoplasm and its relationship to tumour prognosis are discussed...
  5. ncbi request reprint Complement decay accelerating factor (DAF)/CD55 in cancer
    Ian Spendlove
    CR UK Academic Department of Clinical Oncology, Institute of Infections Immunity and Inflammation, The University of Nottingham, NG5 1PB, Nottingham, UK
    Cancer Immunol Immunother 55:987-95. 2006
    ..We will also provide some data providing a potential mechanism by which soluble CD55 can inhibit T-cell function and discuss some of the implications of this data...
  6. ncbi request reprint The role of CD97 in regulating adaptive T-cell responses
    Ian Spendlove
    The University of Nottingham, Academic Clinical Oncology, The City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK
    Adv Exp Med Biol 706:138-48. 2010
    ..This raises a number of questions regarding the dual functions of CD55; regulating complement and stimulating T cells via CD97 interaction and any potential overlap in the consequences of these dual roles...
  7. pmc Upregulation of MICA on high-grade invasive operable breast carcinoma
    Zahra Madjd
    Academic Department of Clinical Oncology, Institute of Infections, Immunity and Inflammation, University of Nottingham, City Hospital, Nottingham, NG5 1PB, United Kingdom
    Cancer Immun 7:17. 2007
    ..Our results suggest that induced expression of MICA may be an indicator of poor prognosis in breast carcinoma and is indicative of a tumour environment that has undergone stresses such as apoptosis, necrosis, or hypoxia...
  8. ncbi request reprint A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55
    Gustav J Ullenhag
    Academic Department of Clinical Oncology, Nottingham City Hospital, Nottingham, United Kingdom
    Clin Cancer Res 12:7389-96. 2006
    ..105AD7 is a human anti-idiotypic antibody mimicking CD55, a glycoprotein, which is more than expressed on colorectal cancer cells and protects them from attack by complement...
  9. ncbi request reprint Cytoplasmic expression of p27(kip1) is associated with a favourable prognosis in colorectal cancer patients
    Nicholas F S Watson
    Section of Gastrointestinal Surgery, University of Nottingham, E Floor, West Block, Queens Medical Centre, Derby Road, Nottingham, NG7 2UH, United Kingdom
    World J Gastroenterol 12:6299-304. 2006
    ..To evaluate the prognostic significance of p27(kip1) in colorectal cancer patients...
  10. doi request reprint Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies?
    Timothy J Duncan
    Academic and Clinical Department of Oncology, University of Nottingham, Nottingham, UK
    Clin Cancer Res 14:3030-5. 2008
    ..This study aims to establish the pattern of expression and effect on prognosis of VEGF in a large population of ovarian cancer patients and to potentially identify a cohort in whom antiangiogenic therapy is appropriate...
  11. ncbi request reprint Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients
    Nicholas F S Watson
    Academic Department of Clinical Oncology, City Hospital, University of Nottingham, Hucknall Road, Nottingham, NG5 1PB, UK
    Cancer Immunol Immunother 55:973-80. 2006
    ..This study has identified CD59 expression as a marker of poor prognosis in colorectal cancer patients...
  12. ncbi request reprint Costimulation via CD55 on human CD4+ T cells mediated by CD97
    Melania Capasso
    Academic Department of Clinical Oncology, Institute of Infection, Immunity and Inflammation, University of Nottingham, City Hospital, Nottingham NG5 1PB, United Kingdom
    J Immunol 177:1070-7. 2006
    ..Our results support a multifaceted role for CD55 in human T cell activation, constituting a further link between innate and adaptive immunity...
  13. ncbi request reprint The use of reverse immunology to identify HLA-A2 binding epitopes in Tie-2
    Judith M Ramage
    Academic Unit of Clinical Oncology, Nottingham University, Hucknall Road, City Hospital, NG5 1PB, Nottingham, UK
    Cancer Immunol Immunother 55:1004-10. 2006
    ..Caution should therefore be employed in the use of both reverse immunology and anchor modification of CTL epitopes in the identification of CTL epitopes for cancer vaccines...
  14. doi request reprint Cytoplasmic p27 expression is an independent prognostic factor in ovarian cancer
    Timothy J Duncan
    Academic and Clinical Department of Oncology, University of Nottingham, Nottingham, UK
    Int J Gynecol Pathol 29:8-18. 2010
    ..These data support a novel role for p27 within the cytoplasm, possibly through effects on apoptosis, cellular motility, and drug resistance...
  15. ncbi request reprint Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients
    Nicholas F S Watson
    Academic Department of Clinical Oncology, University of Nottingham, City Hospital, Nottingham, United Kingdom
    Int J Cancer 118:1445-52. 2006
    ..In contrast, patients with high expression of MICA may be candidates for the antibody therapies, as they should be susceptible to NK killing by antibody dependent cellular cytotoxicity...
  16. ncbi request reprint Identification of an HLA-A*0201 cytotoxic T lymphocyte epitope specific to the endothelial antigen Tie-2
    Judith M Ramage
    Cancer Research UK, Academic Unit of Clinical Oncology, University of Nottingham, City Hospital, Nottingham, United Kingdom
    Int J Cancer 110:245-50. 2004
    ..Our study demonstrates that it is possible to break tolerance to the endothelial antigen Tie-2, suggesting that it may be feasible to design a vaccine to activate CTLs to kill endothelial cells overexpressing Tie-2...
  17. ncbi request reprint Do poor-prognosis breast tumours express membrane cofactor proteins (CD46)?
    Zahra Madjd
    CRC Academic Department of Clinical Oncology, Nottingham City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK
    Cancer Immunol Immunother 54:149-56. 2005
    ..This may suggest that CD46 alone can protect from complement lysis but that loss of CD55 and CD59 are associated with other roles in immune regulation...
  18. pmc High expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas
    Zahra Madjd
    Academic Department of Clinical Oncology, Institute of Infections Immunity and Inflammation, University of Nottingham, City Hospital, Nottingham, UK
    Breast Cancer Res 7:R780-7. 2005
    ..The SC101 mAb is a unique Lewisy/b binding antibody that binds to native and extended Lewisy and Lewisb haptens, displaying no cross reactivity with H type 1, H type 2, Lewisx or normal blood group antigens...
  19. ncbi request reprint Loss of CD55 is associated with aggressive breast tumors
    Zahra Madjd
    Cancer Research UK Academic Unit of Clinical Oncology, University of Nottingham, City Hospital, Nottingham, United Kingdom
    Clin Cancer Res 10:2797-803. 2004
    ..CD55 is overexpressed on some tumor cell lines, and in colorectal carcinomas, it has been shown to be an indicator of poor prognostic...
  20. ncbi request reprint Loss of IFN gamma receptor is an independent prognostic factor in ovarian cancer
    Timothy J Duncan
    Academic and Clinical Department of Oncology, University of Nottingham, Nottingham, UK
    Clin Cancer Res 13:4139-45. 2007
    ..This hypothesis would support the theory of immunoediting in ovarian cancer...
  21. ncbi request reprint The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease
    Phil Rolland
    Academic and Clinical Department of Oncology, Institute of Infections and Immunity, University of Nottingham, Nottingham City Hospital NHS Trust, Nottingham NG5 1PB, UK
    Endocr Relat Cancer 14:73-80. 2007
    ..002) expressions. Though expression correlated with reduced 5-year survival (58.5 vs 73.6%), there was no association with overall disease specific survival. p62 expression may represent a marker of activation of the NFkappaB pathway...
  22. doi request reprint DNA vaccination with T-cell epitopes encoded within Ab molecules induces high-avidity anti-tumor CD8+ T cells
    Victoria A Pudney
    Scancell Limited, Academic Department of Clinical Oncology, University of Nottingham, City Hospital, Nottingham, UK
    Eur J Immunol 40:899-910. 2010
    ..High-avidity responses were capable of efficient anti-tumor activity in vitro and in vivo. This study demonstrates a vaccine strategy to generate high-avidity CTL responses that can be used in anti-tumor and anti-viral vaccine settings...
  23. ncbi request reprint Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer
    Phil Rolland
    Academic and Clinical Department of Oncology, University Hospitals Nottingham, City Hospital Campus, Nottingham, United Kingdom
    Clin Cancer Res 13:3591-6. 2007
    ..We investigated the prognostic potential of HLA class I antigen expression by studying a large series of ovarian cancers...
  24. ncbi request reprint 105Ad7 cancer vaccine stimulates anti-tumour helper and cytotoxic T-cell responses in colorectal cancer patients but repeated immunisations are required to maintain these responses
    L G Durrant
    CRC Department of Clinical Oncology, University of Nottingham, Nottingham, UK
    Int J Cancer 85:87-92. 2000
    ..Our results suggest that 105AD7 can stimulate CD4 and CD8 responses in patients with the appropriate haplotype. However, it may be necessary to continue to immunise, since few patients produce a sustained memory response...
  25. doi request reprint T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55
    G J Ullenhag
    Academic Department of Clinical Oncology, Nottingham City Hospital, Nottingham, NG5 1PB, UK
    Clin Immunol 128:148-54. 2008
    ..Clinical responses and induction of immune responses to both the anti-idiotype and the native CD55 antigen support the use of CD55 as a target in cancer treatment...
  26. ncbi request reprint Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis
    Nicholas F S Watson
    Academic Department of Clinical Oncology, University of Nottingham, City Hospital, Nottingham, United Kingdom
    Int J Cancer 118:6-10. 2006
    ..The existence of these poor prognosis tumors, which may avoid both NK- and T-cell-mediated immune surveillance, has important implications for the design of immunotherapeutic strategies in colorectal cancer...
  27. doi request reprint CD55 costimulation induces differentiation of a discrete T regulatory type 1 cell population with a stable phenotype
    Ruhcha V Sutavani
    Academic Department of Clinical Oncology, University of Nottingham, City Hospital, Nottingham NG5 1PB, United Kingdom
    J Immunol 191:5895-903. 2013
    ....
  28. ncbi request reprint The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer
    Phil Rolland
    Academic and Clinical Department of Oncology, University of Nottingham, City Hospital, Hucknall Road, Nottingham, United Kingdom
    Int J Cancer 120:1311-7. 2007
    ..79 95%ci 1.10-2.89 p = 0.018)...
  29. doi request reprint Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses
    Lindy G Durrant
    Academic Department of Clinical Oncology, City Hospital, University of Nottingham, Hucknall Road, Nottingham NG5 1PB, UK
    Expert Opin Biol Ther 10:735-48. 2010
    ..This has led to the success of monoclonal antibody therapy and the recent approval of prophylactic vaccines that give excellent protection against cervical cancer. Provenge will shortly be the first therapeutic vaccine to be approved...
  30. ncbi request reprint Immunization against tumor cell surface complement-regulatory proteins
    L G Durrant
    Academic Unit of Clinical Oncology, City Hospital, Nottingham, UK
    Curr Opin Investig Drugs 2:959-66. 2001
    ....
  31. pmc Antibodies designed as effective cancer vaccines
    R L Metheringham
    Scancell Limited, Department of Clinical Oncology, University of Nottingham, Nottingham, UK
    MAbs 1:71-85. 2009
    ....
  32. ncbi request reprint Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients
    L G Durrant
    CRC Academic Department of Clinical Oncology, City Hospital, Hucknall Road, NG5 1PB, Nottingham, Nottinghamshire, UK
    Cancer Immunol Immunother 52:638-42. 2003
    ..However, it is a marker of aggression, as colorectal cancer patients whose tumours overexpress CD55 have a significantly reduced 7-year survival...
  33. ncbi request reprint Human anti-idiotypic antibodies can be good immunogens as they target FC receptors on antigen-presenting cells allowing efficient stimulation of both helper and cytotoxic T-cell responses
    L G Durrant
    CRC Academic Unit of Clinical Oncology, University of Nottingham, City Hospital, Nottingham, United Kingdom
    Int J Cancer 92:414-20. 2001
    ..The immunogenicity of other anti-idiotypes may therefore be enhanced by human Fc targeting of antigen-presenting cells...
  34. ncbi request reprint The role of CD55 in protecting the tumour environment from complement attack
    J Morgan
    The University of Nottingham, Cancer Research UK, Nottingham, UK
    Tissue Antigens 60:213-23. 2002
    ..This suggests that it may have a further role to play in protecting cells during inflammation and invasion...
  35. pmc Therapeutic targeting of Lewis(y) and Lewis(b) with a novel monoclonal antibody 692/29
    Philip Noble
    Academic Department of Clinical Oncology, City Hospital Campus, University of Nottingham, Nottingham, UK
    PLoS ONE 8:e54892. 2013
    ..We then assessed the in vivo therapeutic effect of 692/29 using xenograft models...
  36. doi request reprint Using monoclonal antibodies to stimulate antitumor cellular immunity
    Lindy G Durrant
    Academic Department of Clinical Oncology, University of Nottingham, City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK
    Expert Rev Vaccines 10:1093-106. 2011
    ..Combinations of mAbs targeting tumor antigens to activated antigen-presenting cells and mAbs targeting costimulatory receptors may provide effective therapy for a broad range of tumors...
  37. ncbi request reprint Comparison of the immune response to a self antigen after DNA immunisation of HLA*A201/H-2Kb and HHD transgenic mice
    Judith M Ramage
    CR UK Academic Department of Clinical Oncology, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK
    Vaccine 22:1728-31. 2004
    ..HHD mice are therefore useful for studying immunisation strategies for inducing and maintaining CD8 responses to over-expressed self antigens...
  38. pmc CD55 is over-expressed in the tumour environment
    L Li
    CRC Academic Unit of Clinical Oncology, University of Nottingham, City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK
    Br J Cancer 84:80-6. 2001
    ..Although it remains unclear why CD55 is upregulated in the tumour environment its high level of expression on tumour cells and associated endothelium may explain why it is a good target for both imaging and immunotherapy...
  39. ncbi request reprint A novel CEA vaccine stimulates T cell proliferation, gammaIFN secretion and CEA specific CTL responses
    T Parsons
    CRC Academic Department of Clinical Oncology, University of Nottingham, City Hospital, Hucknall Road, Nottingham NG5 1PB, UK
    Vaccine 22:3487-94. 2004
    ..Furthermore, the CTLs killed tumour cells expressing CEA suggesting that this deimmunised antibody could be a useful vaccine for solid tumours...
  40. pmc The ataxia telangiectasia mutated kinase pathway regulates IL-23 expression by human dendritic cells
    Qunwei Wang
    Host Tumour Interactions Group, Academic Unit of Clinical Oncology, University of Nottingham, Nottingham NG5 1PB, United Kingdom
    J Immunol 190:3246-55. 2013
    ..In summary, ATM activation or inhibition, respectively, inhibited or augmented IL-23 release. This novel role of the ATM pathway represents a new therapeutic target in autoimmunity and vaccine development...
  41. ncbi request reprint International conference: progress in vaccination against cancer (PIVAC) 2002, Nottingham, UK
    Robert C Rees
    Department of Life Sciences, Nottingham Trent University, Clifton Lane, Nottingham, NG11 8NS, UK
    Cancer Immunol Immunother 52:403-7. 2003
  42. ncbi request reprint Cancer vaccines entering Phase III clinical trials
    L G Durrant
    CRUK Department of Clinical Oncology, University of Nottingham, City Hospital, Nottingham, NG5 1PB, UK
    Expert Opin Emerg Drugs 8:489-500. 2003
    ..This review outlines some of the approaches that have led to some of these vaccines entering Phase III clinical trials, discusses their modes of action and reports on their current status in trial...
  43. ncbi request reprint Structural and functional characterization of a novel T cell receptor co-regulatory protein complex, CD97-CD55
    Rachel J M Abbott
    Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford, UK
    J Biol Chem 282:22023-32. 2007
    ..This suggests that CD55 might simultaneously regulate both the innate and adaptive immune responses, and we have shown that CD55 can still regulate complement when bound to CD97...
  44. ncbi request reprint Total loss of MHC class I is an independent indicator of good prognosis in breast cancer
    Zahra Madjd
    Cancer Research UK Academic Unit of Clinical Oncology, Nottingham City Hospital, United Kingdom
    Int J Cancer 117:248-55. 2005
    ..001), tumour grade (p = 0.005) and intensity of MHC Class I light and heavy chains expression were shown to be independent prognostic factors predictive of overall survival (p-values HC10 = 0.047 and beta2m = 0.018)...